恒瑞医药港股上市 实现“A+H”双资本平台布局
新华财经香港5月23日电（记者林迎楠）5月23日，江苏恒瑞医药股份有限公司正式在香港交易所挂牌上市，实现“A+H”两地上市。
招股书显示，恒瑞医药此次在港股发行约2.25亿股H股，集资约98.9亿港元。恒瑞医药开盘价为57港元，较发行价上涨约29.40%。截至发稿上涨30.31%，报57.4港元，最新总市值达3790亿港元。
“此次港股上市标志着恒瑞医药在登陆上海证券交易所25年后，正式完成‘A+H’双资本平台布局。”恒瑞医药公司执行董事兼副董事长戴洪斌在上市致辞中表示，登陆港股是恒瑞医药迈向国际资本市场、加速国际化的关键一步，公司将以此次上市为新起点，致力于研发更多具有国际先进水平的创新药，为中国医药行业的高质量发展注入新动力，为全球患者的健康福祉贡献中国力量。
（文章来源：新华财经）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10